Loading...

p53 at the crossroads of MPN treatment

In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of pa...

Full description

Saved in:
Bibliographic Details
Main Author: Plo, Isabelle
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2014
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4118478/
https://ncbi.nlm.nih.gov/pubmed/25082860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-06-579623
Tags: Add Tag
No Tags, Be the first to tag this record!